Pharsight

Duobrii patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US11839656 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US10251895 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US10426787 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US11648256 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US11679115 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

Duobrii is owned by Bausch.

Duobrii contains Halobetasol Propionate; Tazarotene.

Duobrii has a total of 7 drug patents out of which 0 drug patents have expired.

Duobrii was authorised for market use on 25 April, 2019.

Duobrii is available in lotion;topical dosage forms.

Duobrii can be used as topical treatment of plaque psoriasis in adults.

The generics of Duobrii are possible to be released after 06 June, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of DUOBRII before it's drug patent expiration?
More Information on Dosage

DUOBRII family patents

Family Patents